Catalyst Pharma reports Q2 2025 revenue of $146.6M (+19.4% YoY); GAAP net income $52.1M

CATALYST PHARMACEUTICALS, INC.

2025-Q2 EPS reported $0.86 vs consensus $0.39 ▲ beat (+118.4%)

FIRDAPSE Q2 net revenue $84.8M (+9.7% YoY); first-half 2025 net revenue $168.6M (+16.9% YoY).
AGAMREE Q2 net revenue $27.4M (+212.9% YoY); first-half net revenue $49.4M (+398.0% YoY).
FYCOMPA Q2 net revenue $34.3M (-6.0% YoY due to generic entry post LOE).
Non-GAAP diluted EPS $0.68, up from $0.56 in Q2 2024; cash $652.8M, no funded debt.
Reaffirmed FY2025 total revenue guidance of $545M to $565M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.